U.S. bonds sold off as a global trade war escalated, with the Trump administration’s harshest tariffs yet drawing swift retaliation from China and the E.U.

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Saga PLC said underlying pretax profit for fiscal 2026 is expected to be below what it reported for fiscal 2025 due to a material increase in financing costs.